Eli Lilly receives approval for Alzheimer’s drug in India

Investing.com -- Eli Lilly and Company (India) Pvt. has received marketing approval from India’s Central Drugs Standard Control Organization for donanemab, a medication used to treat Alzheimer’s disease, the company announced Tuesday.

The drug is specifically approved for patients in the early symptomatic stages of Alzheimer’s, including those with mild cognitive impairment and those in the mild dementia stage of the disease. Treatment with donanemab requires confirmed amyloid pathology in patients.

This regulatory approval adds India to the markets where Eli Lilly can distribute its Alzheimer’s treatment.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.